Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study.
van der Weijst L, Azria D, Berkovic P, Boisselier P, Briers E, Bultijnck R, Chang-Claude J, Choudhury A, Defraene G, Demontois S, Elliott RM, Ennis D, Faivre-Finn C, Franceschini M, Giandini T, Giraldo A, Gutiérrez-Enríquez S, Herskind C, Higginson DS, Kerns SL, Johnson K, Lambrecht M, Lang P, Ramos M, Rancati T, Rimner A, Rosenstein BS, De Ruysscher D, Salem A, Sangalli C, Seibold P, Sosa Fajardo P, Sperk E, Stobart H, Summersgill H, Surmont V, Symonds P, Taboada-Valladares B, Talbot CJ, Vega A, Veldeman L, Veldwijk MR, Ward T, Webb A, West CML, Lievens Y; REQUITE consortium. van der Weijst L, et al. Among authors: symonds p. Radiother Oncol. 2022 Nov;176:127-137. doi: 10.1016/j.radonc.2022.09.020. Epub 2022 Oct 3. Radiother Oncol. 2022. PMID: 36195214 Free PMC article.
A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort.
Massi MC, Gasperoni F, Ieva F, Paganoni AM, Zunino P, Manzoni A, Franco NR, Veldeman L, Ost P, Fonteyne V, Talbot CJ, Rattay T, Webb A, Symonds PR, Johnson K, Lambrecht M, Haustermans K, De Meerleer G, de Ruysscher D, Vanneste B, Van Limbergen E, Choudhury A, Elliott RM, Sperk E, Herskind C, Veldwijk MR, Avuzzi B, Giandini T, Valdagni R, Cicchetti A, Azria D, Jacquet MF, Rosenstein BS, Stock RG, Collado K, Vega A, Aguado-Barrera ME, Calvo P, Dunning AM, Fachal L, Kerns SL, Payne D, Chang-Claude J, Seibold P, West CML, Rancati T. Massi MC, et al. Among authors: symonds pr. Front Oncol. 2020 Oct 15;10:541281. doi: 10.3389/fonc.2020.541281. eCollection 2020. Front Oncol. 2020. PMID: 33178576 Free PMC article.
Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity.
Franco NR, Massi MC, Ieva F, Manzoni A, Paganoni AM, Zunino P, Veldeman L, Ost P, Fonteyne V, Talbot CJ, Rattay T, Webb A, Johnson K, Lambrecht M, Haustermans K, De Meerleer G, de Ruysscher D, Vanneste B, Van Limbergen E, Choudhury A, Elliott RM, Sperk E, Veldwijk MR, Herskind C, Avuzzi B, Noris Chiorda B, Valdagni R, Azria D, Farcy-Jacquet MP, Brengues M, Rosenstein BS, Stock RG, Vega A, Aguado-Barrera ME, Sosa-Fajardo P, Dunning AM, Fachal L, Kerns SL, Payne D, Chang-Claude J, Seibold P, West CML, Rancati T; REQUITE Consortium Collaborators. Franco NR, et al. Radiother Oncol. 2021 Jun;159:241-248. doi: 10.1016/j.radonc.2021.03.024. Epub 2021 Apr 8. Radiother Oncol. 2021. PMID: 33838170 Free PMC article.
Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study).
Van der Weijst L, Aguado-Barrera ME, Azria D, Berkovic P, Boisselier P, Briers E, Bultijnck R, Calvo-Crespo P, Chang-Claude J, Choudhury A, Defraene G, Demontois S, Dunning AM, Elliott RM, Ennis D, Faivre-Finn C, Franceschini M, Gutiérrez-Enríquez S, Herskind C, Higginson DS, Kerns SL, Johnson K, Mollà M, Lambrecht M, Ramos M, Rancati T, Rimner A, Rosenstein BS, De Ruysscher D, Salem A, Sangalli C, Seibold P, Sosa-Fajardo P, Sperk E, Stobart H, Summersgill H, Surmont V, Symonds P, Taboada-Lorenzo B, Talbot CJ, Valdagni R, Vega A, Veldeman L, Veldwijk MR, Ward T, Webb A, West CML; REQUITE Consortium; Lievens Y. Van der Weijst L, et al. Among authors: symonds p. Lung Cancer. 2022 Apr;166:228-241. doi: 10.1016/j.lungcan.2022.03.010. Epub 2022 Mar 15. Lung Cancer. 2022. PMID: 35334417 Free PMC article.
A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity.
Barnett GC, Thompson D, Fachal L, Kerns S, Talbot C, Elliott RM, Dorling L, Coles CE, Dearnaley DP, Rosenstein BS, Vega A, Symonds P, Yarnold J, Baynes C, Michailidou K, Dennis J, Tyrer JP, Wilkinson JS, Gómez-Caamaño A, Tanteles GA, Platte R, Mayes R, Conroy D, Maranian M, Luccarini C, Gulliford SL, Sydes MR, Hall E, Haviland J, Misra V, Titley J, Bentzen SM, Pharoah PD, Burnet NG, Dunning AM, West CM. Barnett GC, et al. Among authors: symonds p. Radiother Oncol. 2014 May;111(2):178-85. doi: 10.1016/j.radonc.2014.02.012. Epub 2014 Apr 28. Radiother Oncol. 2014. PMID: 24785509
Establishment of a Radiogenomics Consortium.
West C, Rosenstein BS, Alsner J, Azria D, Barnett G, Begg A, Bentzen S, Burnet N, Chang-Claude J, Chuang E, Coles C, De Ruyck K, De Ruysscher D, Dunning A, Elliott R, Fachal L, Hall J, Haustermans K, Herskind C, Hoelscher T, Imai T, Iwakawa M, Jones D, Kulich C; EQUAL-ESTRO; Langendijk JH, O'Neils P, Ozsahin M, Parliament M, Polanski A, Rosenstein B, Seminara D, Symonds P, Talbot C, Thierens H, Vega A, West C, Yarnold J. West C, et al. Among authors: symonds p. Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1295-6. doi: 10.1016/j.ijrobp.2009.12.017. Int J Radiat Oncol Biol Phys. 2010. PMID: 20338472 No abstract available.
Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
Choudhury A, Swindell R, Logue JP, Elliott PA, Livsey JE, Wise M, Symonds P, Wylie JP, Ramani V, Sangar V, Lyons J, Bottomley I, McCaul D, Clarke NW, Kiltie AE, Cowan RA. Choudhury A, et al. Among authors: symonds p. J Clin Oncol. 2011 Feb 20;29(6):733-8. doi: 10.1200/JCO.2010.31.5721. Epub 2011 Jan 4. J Clin Oncol. 2011. PMID: 21205754 Clinical Trial.
Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients.
Zhou C, Taylor S, Tugwood J, Simpson K, Jayson GC, Symonds P, Paul J, Davidson S, Carty K, McCartney E, Rai D, Dive C, West C. Zhou C, et al. Among authors: symonds p. Br J Clin Pharmacol. 2019 Aug;85(8):1781-1789. doi: 10.1111/bcp.13965. Epub 2019 Apr 13. Br J Clin Pharmacol. 2019. PMID: 30980733 Free PMC article. Clinical Trial.
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).
Lane JA, Donovan JL, Young GJ, Davis M, Walsh EI, Avery KNL, Blazeby JM, Mason MD, Martin RM, Peters TJ, Turner EL, Wade J, Bollina P, Catto JWF, Doherty A, Gillatt D, Gnanapragasam V, Hughes O, Kockelbergh R, Kynaston H, Oxley J, Paul A, Paez E, Rosario DJ, Rowe E, Staffurth J, Neal DE, Hamdy FC, Metcalfe C; Prostate Testing for Cancer and Treatment (ProtecT) Study Group. Lane JA, et al. BJU Int. 2022 Sep;130(3):370-380. doi: 10.1111/bju.15739. Epub 2022 May 3. BJU Int. 2022. PMID: 35373443 Free PMC article. Clinical Trial.
279 results